Table 2.
Groups | Total n=434 | Group A* n=149 | Group B† n=145 | Group C‡ n=140 | P |
---|---|---|---|---|---|
Cr after 48 h | 1.99±0.77 | 2.05±0.81 | 1.90±0.63 | 2.00±0.85 | 0.27 |
CIN0.5§ | 8.1% (35) | 6.8% (10) | 6.9% (10) | 10.8% (15) | 0.38 |
CIN0.3|| | 12.4% (53) | 9.7% (14) | 13.3% (19) | 14.4% (20) | 0.44 |
CIN25%# | 8.1% (35) | 6.1% (9) | 7.6% (11) | 10.8% (15) | 0.34 |
*Group A=IV NAC, †Group B=Oral NAC, ‡Group C=Placebo group, §CIN0.5=CIN defined by absolute 0.5 mg/dL increase of serum Cr from baseline, ||CIN0.3=CIN defined by absolute 0.3 mg/dL increase of serum Cr from baseline, #CIN25% = CIN defined by relative 25% increase of serum Cr from baseline